Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer

Pathol Res Pract. 2023 Jan:241:154243. doi: 10.1016/j.prp.2022.154243. Epub 2022 Nov 24.


Prostate cancer diagnosis and early stratification is an important aspect to avoid undertreatment of high-risk prostate cancer patients. Major Vault Protein (MVP) has been proposed as a prognostic biomarker in prostate cancer. PTEN and the immune checkpoint protein B7-H3 interact with MVP and are important in prostate cancer progression and therapy response. We evaluated the expression of MVP by immunohistochemistry of tissue microarray samples from a retrospective cohort consisting of 119 prostate cancer patients. We correlated the protein expression of MVP with clinicopathological characteristics, and protein expression of androgen receptor (AR), PTEN, immune checkpoint proteins B7-H3 and PD-L1. We found MVP to be expressed in 53 % of prostate tumors, and correlated positively with biochemical recurrence (ρ = 0.211/p = 0.021). Furthermore, we found positive correlation of MVP expression with expression of AR (ρ = 0.244/p = 0.009) and the immune checkpoint protein B7-H3 (ρ = 0.200/p = 0.029), but not with PD-L1 (ρ = 0.152/p = 0.117) or PTEN expression (ρ = - 0.034/p = 0.721). Our findings support the notion that expression of MVP is associated with poor prognosis in prostate cancer. The correlation between MVP and immune checkpoint protein B7-H3 in prostate cancer suggests a role for MVP in immunoregulation and drug resistance.

Keywords: Androgen receptor (AR); B7-H3; Immune checkpoint protein; Major Vault Protein (MVP); Prostate cancer.

MeSH terms

  • B7-H1 Antigen* / metabolism
  • Humans
  • Immune Checkpoint Proteins
  • Male
  • Prognosis
  • Prostatic Neoplasms* / pathology
  • Receptors, Androgen
  • Retrospective Studies


  • B7-H1 Antigen
  • Immune Checkpoint Proteins
  • major vault protein
  • Receptors, Androgen